Current Treatment Options in Neurology

, Volume 8, Issue 2, pp 145–157

Modern treatment options for intracerebral hemorrhage

  • William D. Freeman
  • Thomas G. Brott

Opinion statement

Spontaneous intracerebral hemorrhage (ICH) is a devastating neurological event with a 30-day mortality of approximately 40%. Recent research provides new insights into the pathophysiology of ICH-associated edema, with potential molecular and cellular targets for future therapy. Neuroimaging techniques such as gradient echo MRI are yielding insights into cerebral microbleeds and the microangiopathies associated with hypertension and cerebral amyloid angiopathy. Recent literature provides new medical treatment strategies for fever, acute hypertension, and perihematomal edema, and methods of reducing intracranial pressure. Two randomized controlled trials have provided crucial evidence regarding surgical and medical intervention for acute ICH intervention. Recombinant factor VIIa appears to lessen growth of ICH when administered within 4 hours of ictus. Further study of potential efficacy and safety is underway in an international phase III trial. In addition, the Surgical Trial in Intracerebral Hemorrhage reported results from an international randomized trial of 1033 patients who did not show benefit for surgical evacuation of ICH, compared with medical therapy alone. Less invasive surgical methods for hematoma evacuation, studied previously over the past decade, continue to be investigated.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Broderick JP, Brott TG, Tomsick T, et al.: Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg 1993, 78:188–191.PubMedGoogle Scholar
  2. 2.
    Broderick JP, Brott TG, Duldner JE, et al.: Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke 1993, 24:987–993.PubMedGoogle Scholar
  3. 3.
    Brott T, Broderick JP, Kothari R, et al.: Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997, 28:1–5. Thirty-eight percent of ICHs grow by at least 33% in volume within the first day, leading to neurologic deterioration.PubMedGoogle Scholar
  4. 4.
    Broderick JP, Adams HP Jr, Barsan W, et al.: Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999, 30:905–915. Stroke Council guidelines for evaluation and management of patients with intracranial hemorrhage. Review of literature with evidence-based guidelines.PubMedGoogle Scholar
  5. 5.
    Hemphill JC, Bonovich DC, Besmertis L, et al.: The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001, 32:891–897. A useful scale to calculate 30-day mortality in patients with spontaneous ICH.PubMedGoogle Scholar
  6. 6.
    Tuhrim S, Horowitz DR, Sacher M, Godbold JH: Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med 1999, 2:617–621.CrossRefGoogle Scholar
  7. 7.
    Huang CH, Wen-Jone C, Chang WT, et al.: QTc dispersion as a prognostic factor in intracerebral hemorrhage. Am J Emerg Med 2004, 22:141–144.PubMedCrossRefGoogle Scholar
  8. 8.
    Vemmos KN, Tsivgoulis G, Spengos K, et al.: U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004, 255:257–265.PubMedCrossRefGoogle Scholar
  9. 9.
    Fogelholm R, Murros K, Rissanen A, Avikainen S: Admission blood glucose and short-term survival in primary intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatr 2005, 76:349–353.PubMedCrossRefGoogle Scholar
  10. 10.
    Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.Stroke 2005, 36:1588–1593. Up-to-date review of anticoagulation and antiplatelets and risks of central nervous system bleeding.PubMedCrossRefGoogle Scholar
  11. 11.
    Woo D, Sauerbeck LR, Kissela BM, et al.: Genetic and environmental risk factors for intracerebral hemorrhage. Stroke 2002, 33:1190–1196.PubMedCrossRefGoogle Scholar
  12. 12.
    Fang MC, Chang Y, Hylek EM, et al.: Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.Ann Intern Med 2004, 141:745–752.PubMedGoogle Scholar
  13. 13.
    Smith EE, Rosand J, Knudsen KA, et al.: Leukoariosis is associated with warfarin-related hemorrhage following ischemic stroke.Neurology 2002, 59:193–197.PubMedGoogle Scholar
  14. 14.
    Jeerakathil T, Wolf PA, Beiser A, et al.: Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study.Stroke 2004, 35:1831–1835.PubMedCrossRefGoogle Scholar
  15. 15.
    Nighoghossian N, Hermier M, Adeleine P, et al.: Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study.Stroke 2002, 33:735–742.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee SH, Bae HJ, Kwon SJ, et al.: Cerebral microbleeds are regionally associated with intracerebral hemorrhage. Neurology 2004, 62:72–76.PubMedGoogle Scholar
  17. 17.
    Greenberg SM, Eng JA, Ning M, et al.: Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage.Stroke 2004, 35:1415–1420.PubMedCrossRefGoogle Scholar
  18. 18.
    Roob G, Schmidt E, Kapeller P, et al.: MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 1999, 52:991–994.PubMedGoogle Scholar
  19. 19.
    Qureshi AI, Tuhrim S, Broderick JP, et al.: Spontaneous intracerebral hemorrhage.N Eng J Med 2001, 344:1450–1460.CrossRefGoogle Scholar
  20. 20.
    Fisher CM: Pathological observations in hypertensive cerebral hemorrhage.J Neuropath Exp Neurol 1971, 30:536–550.PubMedCrossRefGoogle Scholar
  21. 21.
    Garcia JH, Ho KL: Pathology of hypertensive cerebral arteriopathy.Neurosurg Clin N Am 1992, 3:497–507.PubMedGoogle Scholar
  22. 22.
    Schellinger PD, Fiebach JB: Intracranial hemorrhage: the role of magnetic resonance imaging.Neurocrit Care 2004, 1:31–46.PubMedCrossRefGoogle Scholar
  23. 23.
    Kothari RU, Brott T, Broderick JP, et al.: The ABCs of measuring intracerebral hemorrhage volumes.Stroke 1996, 27:1304–1305.PubMedGoogle Scholar
  24. 24.
    Zuccarello M, Brott T, Derex L, et al.: Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study.Stroke 1999, 30:1833–1839.PubMedGoogle Scholar
  25. 25.
    Yu YL, Kumana CR, Lauder IJ, et al.: Treatment of acute cerebral hemorrhage with intravenous glycerol. A double blind, placebo-controlled, randomized trial. Stroke 1992, 23:967–971.PubMedGoogle Scholar
  26. 26.
    Haley EC, Thompson JLP, Levin B, et al.: Gavestinel does not improve outcome after acute intracerebral hemorrhage.Stroke 2005, 36:1006–1010.PubMedCrossRefGoogle Scholar
  27. 27.
    Poungvarin N, Bhoopat W, Viriyavejakul A, et al.: Effects of dexamethasone in primary supratentorial intracerebral hemorrhage.N Engl J Med 1987, 316:1229–1233.PubMedCrossRefGoogle Scholar
  28. 28.
    Tellez H, Bauer RB: Dexamethasone as treatment in cerebrovascular disease. 1. A controlled study in intracerebral hemorrhage.Stroke 1973, 4:541–546.PubMedGoogle Scholar
  29. 29.
    Piriyawat P, Morgenstern LB, Yawn D, et al.: Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: a pilot study.Neurocrit Care 2004, 1:47–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF: Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage.Mayo Clin Proc 2005, 80:420–433. Comprehensive review of standard and emerging medical and surgical strategies for patients with ICH.PubMedGoogle Scholar
  31. 31.
    Powers WJ, Zazulia AR, Videen TO, et al.: Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage.Neurology 2001, 57:18–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Toyoda K, Okada Y, Minematsu K, et al.: Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage.Neurology 2005, 65:1000–1004.PubMedCrossRefGoogle Scholar
  33. 33.
    Qureshi AI, Bliwise DL, Bliwise NG, et al.: Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med 1999, 27:480–485.PubMedCrossRefGoogle Scholar
  34. 34.
    Qureshi AI, Wilson DA, Hanley DF, Traystman RJ: Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage.Crit Care Med 1999, 27:965–971.PubMedCrossRefGoogle Scholar
  35. 35.
    Qureshi AI, Mohammad YM, Yahia AM, et al.: A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med 2005, 20:34–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Zazulia AR, Diringer MN, Videen TO, et al.: Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage.J Cereb Blood Flow Metab 2001, 21:804–810.PubMedCrossRefGoogle Scholar
  37. 37.
    Carhuapoma JR, Gupta K, Coplin WM, et al.: Treatment of refractory fever in the neurosciences critical care unit using a novel, water-circulating cooling device. A single-center pilot experience.J Neurosurg Anesthesiol 2003, 15:313–318.PubMedCrossRefGoogle Scholar
  38. 38.
    Diringer MN,Neurocritical Care Fever Reduction Trial Group: Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system. Crit Care Med 2004, 32:559–564. Details the use of a central venous catheter for cooling febrile neurocritical care patients.PubMedCrossRefGoogle Scholar
  39. 39.
    Leira R, Davalos A, Silva Y, et al.: Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors.Neurology 2004, 10:461–467.Google Scholar
  40. 40.
    Marion DW: Controlled normothermia in neurologic intensive care.Crit Care Med 2004, 32(Suppl):S43-S45.PubMedCrossRefGoogle Scholar
  41. 41.
    Ritter AM, Robertson CS: Cerebral metabolism. Neurosurg Clin N Am 1994, 5:633–645.PubMedGoogle Scholar
  42. 42.
    Mayer SA, Kowalski RG, Presciutti M, et al.: Clinical trial of a novel surface cooling system for fever control in neurocritical care patients. Crit Care Med 2004, 32:2508–2515. Details the use of a cooling pad system applied to the trunk and thighs for cooling febrile neurocritical care patients.PubMedCrossRefGoogle Scholar
  43. 43.
    Doufas AG, Sessler DI: Physiology and clinical relevance of induced hypothermia. Neurocrit Care 2004, 1:489–498. An excellent review of physiology, implications, and therapies for induced hypothermia and shivering.PubMedCrossRefGoogle Scholar
  44. 44.
    O’Grady NP, Barie PS, Bartlett J, et al.: Practice parameters for evaluating new fever in critically ill adult patients. Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. Crit Care Med 1998, 26:392–408. Guidelines for evaluating critically ill patients with fever.PubMedCrossRefGoogle Scholar
  45. 45.
    Frank SM, Fleisher LA, Breslow MJ, et al.: Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomized clinical trial. JAMA 1997, 277:1127–1134.PubMedCrossRefGoogle Scholar
  46. 46.
    Doufas AG, Lin CM, Suleman MI, et al.: Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke 2003, 34:1218–1223.PubMedCrossRefGoogle Scholar
  47. 47.
    Mokhtarani M, Mahgoub AN, Morioka N, et al.: Buspirone and meperidine synergistically reduce the shivering threshold. Anesth Analg 2001, 93:1233–1239.PubMedCrossRefGoogle Scholar
  48. 48.
    Fujii Y, Tanaka R, Takeuchi S, et al.: Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg1994, 80:51–57.PubMedGoogle Scholar
  49. 49.
    Kazui S, Minematsu K, Yamamoto H, et al.: Predisposing factors to enlargement of spontaneous intracerebral hemorrhage. Stroke 1997, 28:2370–2375.PubMedGoogle Scholar
  50. 50.
    Ohwaki K, Yano E, Nagashima H, et al.: Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004, 35:1364–1367. Systolic blood pressure of 160 mm Hg or more was significantly associated with hematoma enlargement, compared with pressure of 150 mm Hg or less (P = 0.025).PubMedCrossRefGoogle Scholar
  51. 51.
    Mayer SA, Brun NC, Begtrup K, et al.: Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777–785. Three hundred and ninety-nine patients with acute ICH were randomized to placebo versus 40 _g/kg, 80 _g/kg, or 160_g/kg intravenous bolus of rFVII. A dose-dependent effect on reducing hematoma growth was evident.PubMedCrossRefGoogle Scholar
  52. 52.
    NovoSeven. Package Insert. Princeton, NJ: Novo Nordisk; 2005.Google Scholar
  53. 53.
    Erhardtsen E: Ongoing NovoSeven trials. Intensive Care Med 2002, 28(Suppl 2):S248-S256.PubMedCrossRefGoogle Scholar
  54. 54.
    Freeman WD, Brott TG, Barrett KM, et al.: Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004, 79:1495–1500. Small study of seven patients with warfarin-related ICH treated with rFVIIa (15-90 μg/kg) with rapid anticoagulation. INR reversal was rapid and safe, allowing for two neurosurgical interventions.PubMedGoogle Scholar
  55. 55.
    Fewel ME, Park P: The emerging role of recombinantactivated factor VII in neurocritical care. Neurocrit Care 2004, 1:19–30. A concise review of rFVIIa for neurointensivists for various indications.PubMedCrossRefGoogle Scholar
  56. 56.
    Hart RG: What causes intracerebral hemorrhage during warfarin therapy? Neurology 2000, 55:907–908.PubMedGoogle Scholar
  57. 57.
    Franke CL, de Jonge J, van Swieten JC, et al.: Intracerebral hemorrhage during anticoagulation treatment. Stroke 1990, 21:726–730.PubMedGoogle Scholar
  58. 58.
    Rosand J, Eckman MH, Knudsen KA, et al.: The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004, 164:880–884.PubMedCrossRefGoogle Scholar
  59. 59.
    Sjoblom L, Hardemark HG, Lindgren A, et al.: Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001, 32:2567–2574. Large study of warfarin-related intracranial hemorrhage, citing a 30-day mortality of 50%.PubMedGoogle Scholar
  60. 60.
    Neau JP, Couderq C, Ingrand P, et al.: Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis 2001, 11:195–200.PubMedCrossRefGoogle Scholar
  61. 61.
    Yasaka M, Minematsu K, Naritomi H, et al.: Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003, 89:278–283.PubMedGoogle Scholar
  62. 62.
    Brody DL, Aiyagari V, Shackleford AM, Diringer MN: Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005, 2:263–267.PubMedCrossRefGoogle Scholar
  63. 63.
    Park P, Fewel ME, Garton HJ, et al.: Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophiliac neurosurgical patients. Neurosurgery 2003, 53:34–38.PubMedCrossRefGoogle Scholar
  64. 64.
    Lin J, Hanigan WC, Tarantino M, Wang J: The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003, 98:737–740.PubMedGoogle Scholar
  65. 65.
    Deveras RA, Kessler CM: Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002, 137:884–888. This study used 15-90 μg/kg intravenous dose of rFVIIa to rapidly and safely reverse warfarin anticoagulation in medical patients.PubMedGoogle Scholar
  66. 66.
    Sorenson B, Johansen P, Nielson GL, et al.: Reversal of International Normalized Ratio with recombinant factor VIIa in central nervous system bleeding during warfarin thrombophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003, 14:469–477. Warfarin-anticoagulation reversal with 10-to 40-μg/kg doses of rFVIIa.CrossRefGoogle Scholar
  67. 67.
    Hirsh J, Fuster V, Ansell J, et al.: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003, 41:1633–1652. Anticoagulation guidelines for anticoagulation intensity, dosing, and reversal.PubMedCrossRefGoogle Scholar
  68. 68.
    AquaMEPHYTON. In Physician’s Desk Reference. Montvale, NJ: Medical Economics Company, Inc.; 2001.Google Scholar
  69. 69.
    Riegert-Johnson DL, Volcheck GW: The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002, 89:400–406.PubMedCrossRefGoogle Scholar
  70. 70.
    Fiore LD, Scola MA, Cantillon CE, Brophy MT: Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001, 11:175–183.PubMedCrossRefGoogle Scholar
  71. 71.
    Olson JD: Mechanisms of hemostasis. Effect on intracerebral hemorrhage. Stroke 1993, 24(Suppl):I109-I114.PubMedGoogle Scholar
  72. 72.
    Schulman S: Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675–683. A review of anticoagulant therapy with nomogram for prothrombin complex concentrates dosing.PubMedCrossRefGoogle Scholar
  73. 73.
    Akdemir H, Selcuklu A, Pasaoglu A, et al.: Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase. Neurosurg Rev 1995, 18:95–100.PubMedCrossRefGoogle Scholar
  74. 74.
    Coplin WM, Vinas FC, Agris JM, et al.: A cohort study of the safety and feasibility of intraventricular urokinase for nonaneurysmal spontaneous intraventricular hemorrhage. Stroke 1998, 29:1573–1579.PubMedGoogle Scholar
  75. 75.
    Naff NJ, Carhuapoma JR, Williams MA, et al.: Treatment of intraventricular hemorrhage with urokinase: effects on 30-day survival. Stroke 2000, 31:841–847.PubMedGoogle Scholar
  76. 76.
    Tung MY, Ong PL, Seow WT, Tan KK: A study on the efficacy of intraventricular urokinase in the treatment of intraventricular haemorrhage. Br J Neurosurg 1998, 12:234–239.PubMedCrossRefGoogle Scholar
  77. 77.
    Naff NJ, Hanley DF, Keyl PM, et al.: Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized double-blind, controlled trial. Neurosurgery 2004, 54:577–583.PubMedCrossRefGoogle Scholar
  78. 78.
    Engelhard HH, Andrews CO, Slavin KV, Charbel FT: Current management of intraventricular hemorrhage. Surg Neurol 2003, 60:15–22. A concise review of IVH and protocol for intraventricular rtPA administration.PubMedCrossRefGoogle Scholar
  79. 79.
    Hanley DF, Hacke W: Critical care and emergency medicine neurology in stroke. Stroke 2005, 36:205–207.PubMedCrossRefGoogle Scholar
  80. 80.
    Xi G, Keep RF, Hoff JT: Pathophysiology of brain edema formation. Neurosurg Clin N Am 2002, 13:371–383.PubMedCrossRefGoogle Scholar
  81. 81.
    Gebel JM, Jauch EC, Brott TG, et al.: Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002, 33:2636–2641.PubMedCrossRefGoogle Scholar
  82. 82.
    Gebel JM, Jauch EC, Brott TG, et al.: Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002, 33:2631–2635.PubMedCrossRefGoogle Scholar
  83. 83.
    Xi G, Wagner KR, Keep RF, et al.: Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 1998, 29:2580–2586.PubMedGoogle Scholar
  84. 84.
    Gebel JM, Brott TG, Sila CA, et al.: Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage.Stroke 2000, 31:596–600.PubMedGoogle Scholar
  85. 85.
    Wagner KR, Xi G, Hua Y, et al.: Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection.J Neurosurg 1999, 90:491–498.PubMedCrossRefGoogle Scholar
  86. 86.
    Rincon F, Mayer SA: Novel therapies for intracerebral hemorrhage.Curr Opin Crit Care 2004, 10:94–100.PubMedCrossRefGoogle Scholar
  87. 87.
    Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial. Neurosurgery 2002, 51:628–637.PubMedCrossRefGoogle Scholar
  88. 88.
    Larive LL, Rhoney DH, Parker D Jr et al.: Introducing hypertonic saline for cerebral edema: an academic center experience.Neurocrit Care 2004, 1:435–440.PubMedCrossRefGoogle Scholar
  89. 89.
    Qureshi AI, Wilson DA, Traystman RJ: Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol and hypertonic saline.Neurosurgery 1999, 44:1055–1063.PubMedCrossRefGoogle Scholar
  90. 90.
    Ogden AT, Mayer SA, Connolly ES Jr: Hyperosmolar agents in neurosurgical practice: the evolving role of hypertonic saline.Neurosurgery 2005, 57:207–215.PubMedCrossRefGoogle Scholar
  91. 91.
    Qureshi AI, Suarez JI, Bhardwaj A, et al.: Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: effect on intracranial pressure and lateral displacement of the brain. Crit Care Med 1998, 26:440–446.PubMedCrossRefGoogle Scholar
  92. 92.
    Suarez JI, Qureshi AI, Bhardwaj A, et al.: Treatment of refractory intracranial hypertension with 23.4% saline. Crit Care Med 1998, 26:1118–1122.PubMedCrossRefGoogle Scholar
  93. 93.
    Fernandes HM, Gregson B, Siddique S, Mendelow AD: Surgery in intracerebral hemorrhage. The uncertainty continues. Stroke 2000, 31:2511–2516.PubMedGoogle Scholar
  94. 94.
    Mendelow AD, Gregson BA, Fernandes HM, et al.: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387–397. Most recent large surgical trial for acute supratentorial ICH. No benefit for surgery was found, compared with conservative therapy.PubMedGoogle Scholar
  95. 95.
    Nishihara T, Nagata K, Tanaka S, et al.: Newly developed endoscopic instruments for the removal of intracerebral hematoma. Neurocrit Care 2005, 2:67–74.PubMedCrossRefGoogle Scholar
  96. 96.
    Vespa P, McArthur D, Miller C, et al.: Frameless stereotactic aspiration and thrombolysis of deep intracerebral hemorrhage is associated with reduction of hemorrhage volume and neurologic improvement. Neurocrit Care 2005, 2:274–281.PubMedCrossRefGoogle Scholar
  97. 97.
    Teernstra OP, Evers SM, Lodder J, et al.: Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA). Stroke 2003, 34:968–974.PubMedCrossRefGoogle Scholar
  98. 98.
    Murthy JM, Chowdary GV, Murthy TV, et al.: Decompressive craniectomy with clot evacuation in large hemispheric hypertensive intracerebral hemorrhage. Neurocrit Care 2005, 2:258–262.PubMedCrossRefGoogle Scholar

Copyright information

© by Current Science Inc 2006

Authors and Affiliations

  • William D. Freeman
  • Thomas G. Brott
    • 1
  1. 1.Mayo Clinic JacksonvilleJacksonvilleUSA

Personalised recommendations